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Abstract
Objective: Adrenomedullin, a recently discovered peptide with hypotensive effects, has been shown
to be elevated in glomerular diseases. In this study, we investigated the relationship between the
plasma adrenomedullin and renal tubulointerstitial lesion in patients with mesangial proliferative
glomerulonephritis.
Methods: Twenty-six patients with a normal renal function, diagnosed histologically with mesangial
proliferative glomerulonephritis with (n = 1) or without immunoglobulin A composure (n = 25), were
enrolled in this study. Eighteen healthy volunteers were enrolled as controls. Patients were divided
into two groups according to the degree of tubulointerstitial lesion. Plasma adrenomedullin level
was measured by an adrenomedullin-specific radioimmunoassay.
Results: Plasma adrenomedullin concentrations were higher in patients with mesangial proliferative
glomerulonephritis than in healthy volunteers (5.71 x 10-12 ± 0.37 x 10-12 vs 2.12 x 10-12 ± 0.15 x
10-12 mol/L; p<0.01). Plasma adrenomedullin was also higher in patients with severe
tubulointerstitial lesion than those with mild lesions (6.69 x 10-12 ± 0.25 x 10-12 vs 4.58 x 10-12 ± 0.13
x 10-12 mol/L; p<0.01).
Conclusion: Plasma adrenomedullin concentrations increase in patients with mesangial proliferative
glomerulonephritis, and the degree of elevation correlates with tubulointerstitial lesion.
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INTRODUCTION
Adrenomedullin (AM) is a peptide with hypotensive
effects. It was originally isolated from extracts of human
pheochromocytoma tissue, but now is known to be
widely distributed in various organs including the kidney.
Adrenomedullin has many biological properties; among
which the effects on circulation control, natriuresis, and
diuresis seem to be most outstanding and characteristic
(1,2). It has been shown that AM can be produced by
mesangial cells (MC), and AM suppresses MC
mitogenesis (3,4), suggesting a possible role of AM in
the development of glomerulonephritis. Plasma AM
concentration is elevated in patients with renal failure
(5), glomerulonephritis (6), immunoglobulin (Ig) A
nephropathy (7), and diabetic nephropathy (8). Although
tubulointerstitial lesion is an important factor in the
progression of renal diseases (including glomerular
diseases), there has been no study investigating the
re la t ionship  be tween p lasma AM and renal
tubulointerstitial lesion. In this study, we investigated
the correlation between the plasma AM concentration
and the degree of tubulointerstitial lesion in patients with
mesangial proliferative glomerulonephritis (MsPGN).
METHODS
Patient selection
We studied 26 Chinese patients with a histological
diagnosis of MsPGN, one of whom had mesangial IgA
deposits. The mean age was 30 years (range, 15-54
years). None of the patients had renal insufficiency as
determined by serum creatinine, glomerular filtration
rate, and blood urea nitrogen. None of the patients had
coexisting cardiac disease, connective tissue disease, or
diabetes mellitus. Patients with hypertension or edema
were also excluded from the study. The patients were
divided into mild and severe groups according to the
degree of tubulointerstitial lesion. In the mild group, there
was no lesion or only focal lymphocyte and macrophage
infiltration in the tubulointerstitial; in the severe group,
there was diffused or multifocal lymphocyte and
macrophage infiltration or focal fibrosis in tubulo-
interstitial. We further studied 18 healthy volunteers, aged
21 to 60 years, as controls.
Procedures
Blood samples were collected in the morning of kidney
biopsy with ethylenediaminetetraacetic acid-2Na (1 mg/
mL) and Aprotinin (20 KJU; Bayer, Germany), and then
separated by centrifugation at 4oC and stored at –70oC
before extraction. Plasma samples were diluted with 2
mL of saline and 0.08 mL of 1 M HCl. The diluted plasma
samples were then loaded onto a prewashed Sep-Pak C18
cartridge (Waters, Milford, MA), and the absorbed
materials were eluted and lyophilized. The lyophilizate
was dissolved, and the plasma AM level was measured
by using AM-specific radioimmunoassay according to
the manufacturer's protocol (Phoenix Pharmaceuticals,
Belmont, US). Briefly, initial radioimmunoassay
reactions were set up in polystyrene tubes including total
counts, nonspecific binding, total binding, standard, and
sample groups. Primary antibody was added to each tube,
vortexed, and incubated 16 hours at 4oC. Then 125I-
peptide was added, vortexed, and incubated for 16 hours
at 4oC. Goat anti-rabbit IgG serum and normal rabbit
serum were then added, vortexed, and incubated at room
temperature for 90 minutes. Radioimmunoassay buffer
was then added, vortexed, and centrifuged for 20 minutes
at 3000 rpm. All the supernatant except total count tubes
were then carefully aspirated immediately after
centrifugation. A gamma counter was used to count the
pellets. A standard curve was constructed by plotting the
standard peptide concentrations. All samples were
measured by duplicate.
Statistical analysis
Data are given as mean ± standard deviation unless
otherwise specified. Statistical differences between
experimental groups were determined with Student’s t
test and one-way analysis of variance as appropriate, using
InStat 2.03 software (Cahners In-Stat Group, Newton,
US). A p value less than 0.05 was considered to be
statistically significant. All probabilities were two-tailed.
RESULTS
The demographic and clinical characteristics of the
patients and controls are summarized in Table 1. There
were differences in age and renal function between the
cases and controls. The degree of proteinuria and severity
of glomerular lesions were similar between mild and
severe tubulointerstitial lesion groups.
The results of plasma AM concentration in the three
groups are summarized in Fig. 1. Plasma AM
concentrations were significantly higher in patients with
MsPGN than controls (5.71 x 10-12 ± 0.37 x 10-12 vs
2.12 x 10-12 ± 0.15 x 10-12 mol/L; p<0.01). Plasma AM
was also higher in patients with severe tubulointerstitial
lesion than those with mild lesion (6.69 x 10-12 ± 0.25 x
10-12 vs 4.58 x 10-12 ± 0.13 x 10-12 mol/L; p<0.01).
DISCUSSION
Adrenomedullin is a recently discovered vasodilatory
peptide. It is found ubiquitously in many tissues and
organs, and is particularly abundant in heart, kidney,
lung, and endocrine glands (1,2). Renal glomerular MC
and tubular cells could produce and secrete AM, which
is involved in the regulation of renal function in autocrine
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and paracrine modes. The plasma concentration of AM
increases under pathological conditions such as
congestive heart failure, myocardial infarction,
hypertension, and renal diseases (5-9). In these
conditions, AM may be produced in response to volume
expansion, hypertension, and activated humoral factors,
such as catecholamine and the renin-angiotensin system.
The administration of low-dose AM exerted diuretic and
natriuretic actions without inducing hypotension. In
contrast, high-dose AM reduced mean arterial pressure
and increased cardiac output, glomerular filtration rate,
effective renal plasma flow, urine flow, and urinary
sodium excretion (10). Current evidence suggests that
AM may have an important role in homeostasis.
Kubo et al (6) reported that plasma AM concentrations
were higher in patients with chronic glomerulonephritis
and proteinuria than in healthy volunteers, and the degree
of elevation correlated with the degree of proteinuria.
Plasma AM concentrations were also significantly
increased in patients with IgA nephropathy compared
with healthy controls. Plasma AM level showed a positive
correlation with serum creatinine and blood urea
nitrogen, so it was possible that impaired renal function
itself caused the increase in plasma AM concentration.
However, plasma AM concentrations are still sig-
nificantly increased in patients with glomerulonephritis
and normal renal function as compared with healthy
volunteers, suggesting that changes in plasma AM level
may be caused by the kidney disease itself (7).
Previous studies of AM focused on the relationship
between AM and the glomerular lesion. However, the
progression of renal diseases is closely correlated with
tubulointerstitial lesion. The natriuretic and diuretic
actions of AM reflect unique actions of the peptide on
renal blood flow and tubular function. Therefore, AM
may have an important role in the progression of renal
failure. In this study, we investigated the relationship
between plasma AM and the degree of tubulointerstitial
lesion. The results showed that in patients with MsPGN,
the plasma AM level increased significantly when
compared with healthy volunteers. Moreover, the plasma
AM concentration in patients with severe tubulo-
interstitial lesion is higher than that in patients with mild
tubulointerstitial lesion. Because all patients had normal
renal function, the increase of plasma AM could not be
explained by decreased renal clearance. In addition, none
of these patients had hypertension or edema. Therefore,
the compensative increase of plasma AM attributed to
volume expansion or hypertension was unlikely. Taken
together, data in this study suggested that the increase of
plasma AM correlated with the severity of tubulo-
interstitial lesion. In this study, the origin of the
circulating AM was not determined. To date, there is no
report about the relationship between plasma AM level
and intrarenal AM expression, although cultured MC and
tubular cells could produce AM in vitro.
Chini et al (3) reported that AM suppressed the MC
proliferation induced by platelet-derived growth factor,
epidermal growth factor, and endothelin-1, as well as
the generation of reactive oxygen species by MC and
macrophages. This recent study demonstrated that AM
can antagonize the biological action of transforming
growth factor beta-1 on extracellular matrix accumulation
in the human renal tubular epithelial cell line (HK-2)
Table 1. Demographic and clinical characteristics.
Group No. of participants Renal function Urine protein Glomerular lesion     Tubulointerstitial lesion
Control 18 Normal <150 mg Normal Normal
Mild lesion 12 Normal 0.5-1.2 g Mild mesangial cell No lesion or only focal
 group   proliferation   lymphocyte and macrophage
  infiltration in the tubulointerstitium
Severe lesion 14 Normal 0.8-1.5g Mild mesangial cell Diffuse or much focal
  group   proliferation   lymphocyte and macrophage
  infiltration or small focal
  fibrosis in the tubulointerstium
Figure 1. Plasma adrenomedullin levels in the three groups.
*p<0.01 vs control group.
#p<0.01 vs mild lesion group.
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(11). As a result, we speculate that the increase of plasma
AM level in glomerulonephritis with tubulointerstitial
lesion may be an adaptive compensation, which may have
a protective role in the progression of tubulointerstitial
lesion.
In conclusion, it has been demonstrated that plasma AM
concentration increases in patients with MsPGN, and the
degree of elevation correlates with the degree of tubu-
lointerstitial lesion. Adrenomedullin may participate in
the pathophysiology and progression of renal tubulo-
interstitial lesion.
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